| |
| | APA: Galantamine Hydrobromide Delays Alzheimer's Symptoms by 18 Months (Site not responding. Last check: 2007-11-05) |
 | | For this three-year analysis, Alzheimer’s disease patients, who were involved in one of two earlier double-blind trials comparing galantamine hydrobromide to placebo, were asked if they would like to participate in further research. |
 | | The investigators, led by Murray Raskind, MD, director of the Alzheimer’s Disease Research Center at the department of Veteran’s Affairs, Puget Sound Healthcare System, in Tacoma, Washington, assessed the cognition of the participants at 12, 24, and 36 months and compared it to expected rates of cognitive decline in untreated patients. |
 | | The investigators estimate that galantamine hydrobromide delays progression of Alzheimer’s disease by approximately 18 months. |
| www.pslgroup.com /dg/21576a.htm (366 words) |
|